chartexchange

BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

The Motley Fool | Nov 11, 2026 3:40 PM EST

Investors choosing between BioNTech (NASDAQ:BNTX) and Vertex Pharmaceuticals (NASDAQ:VRTX) must weigh the massive potential of mRNA cancer research against the reliable, high-margin cash flows of a dominant cystic fibrosis treatment leader. BioNTech is famous for its role in COVID-19 vaccines but is now pivoting toward oncology. Vertex Pharmaceuticals dominates the cystic fibrosis market while expanding into new areas like gene therapy. Both companies represent different stages of the biotechnology lifecycle, making them popular comparisons for healthcare investors seeking long-term growth. BioNTech focuses on developing immunotherapies and mRNA-based medicines for cancer and infectious diseases. In its latest annual report, filed for the period ending December 31, 2025, the company noted it employed roughly 8,052 people. While it gained global fame for its vaccine success, the business strategy now centers on commercializing oncology treatments in the United States and other major global markets. Continue reading

Read original article